As an interventional cardiologist in the UK, what do the results from the ODYSSEY Outcomes Trial and price reductions mean to the clinician at the front lines of cardiology care as far as access to and triggers for deploying a PCSK9 inhibitor?

As an interventional cardiologist in the UK, what do the results from the ODYSSEY Outcomes Trial and price reductions mean to the clinician at the front lines of cardiology care as far as access to and triggers for deploying a PCSK9 inhibitor?

As an interventional cardiologist in the UK, what do the results from the ODYSSEY Outcomes Trial and price reductions mean to the clinician at the front lines of cardiology care as far as access to and triggers for deploying a PCSK9 inhibitor?


Created by

 CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Interventional Cardiologist's Perspective

Presenter

Keith A.A. Fox, MBChB, FRCP, FMedSci

Keith A.A. Fox, MBChB, FRCP, FMedSci

Professor, University of Edinburgh Department of Cardiovascular Medicine Professor, University and Royal Infirmary Edinburgh, United Kingdom